Advertisement

Drugs & Therapy Perspectives

, Volume 24, Issue 12, pp 25–26 | Cite as

Transdermal drug delivery has ideal properties in the elderly

Practical Issues and Updates
  • 47 Downloads

The transdermal route of drug delivery has many advantages over other routes; some of these advantages are particularly applicable to the elderly population.

Transdermal route ideal for drug delivery

Despite its barrier function, many drugs can pass through the skin.[1] Transdermal drug-delivery systems, therefore, have been developed. Passive-diffusion transdermal systems are available as reservoir or matrix types (figure 1). The reservoir system utilizes a membrane to control the drug release rate and, therefore, the drug is released constantly.[1] Matrix systems are limited by the rate of the drug’s skin penetration, and can be classified as simple matrix (the drug is manufactured in a polymer layer that controls drug delivery), drug-in-adhesive system (has the advantage of being thin and flexible) or multilayer matrix (superposition of layers with varying drug concentrations create a concentration gradient).[1]

References

  1. 1.
    Kaestli LZ, Wasilewski-Rasca AF, Bonnabry P, et al. Use of transdermal drug formulations in the elderly. Drugs Aging 2008; 25(4): 269–80PubMedCrossRefGoogle Scholar
  2. 2.
    Pergolizzi J, Böger RH, Budd K, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an international expert panel with focus on the six clinically most often used World Health Organization step III opioids (bupre-norphine, fentanyl, hydromorphone, methadone, morphine, oxyco-done). Pain Pract 2008 Jul–Aug; 8(4): 287–313PubMedCrossRefGoogle Scholar
  3. 3.
    Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006; 23(5): 357–75PubMedCrossRefGoogle Scholar
  4. 4.
    Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005 Nov; 11(4): 221–35PubMedCrossRefGoogle Scholar
  5. 5.
    Davis MP. Management of cancer pain: focus on new opioid analgesic formulations. Am J Cancer 2006; 5(3): 171–82CrossRefGoogle Scholar
  6. 6.
    Kornick CA, Santiago-Palma J, Moryl N, et al. Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Saf 2003; 26(13): 951–73PubMedCrossRefGoogle Scholar
  7. 7.
    Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia. Expert Rev Neurother 2007 Nov; 7(11): 1457–63PubMedCrossRefGoogle Scholar
  8. 8.
    Frampton JE, Plosker GL. Selegiline transdermal system: in the treatment of major depressive disorder. Drugs 2007; 67(2): 257–65PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Personalised recommendations